AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals [MarketWatch]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: MarketWatch
treatment for Alzheimer's disease failed to slow or prevent cognitive decline in patients with a specific genetic mutation that causes early-onset disease. The trial involved 252 people who are members of the world's biggest extended family with Autosomal Dominant Alzheimer's Disease, or ADAD, in Colombia. Some two thirds of those enrolled had the Presenilin 1 E280A mutation which typically causes cognitive impairment due to Alzheimer's disease around age 44. The participants were randomized to receive the treatment called crenezumab or placebo over a period of five to eight years. Crenezumab was well tolerated and no new safety issues were identified. The company will present initial data at the Alzheimer's Association International Conference on August 2. "While we are disappointed that the primary endpoints were not met, crenezumab's safety profile and the favorable numerical differences observed across primary, secondary and exploratory endpoints, warrant further analyses of the d
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58% [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewswire
- AC Immune Announces Upcoming Presentations at AD/PD™ 2024 [Yahoo! Finance]Yahoo! Finance
- AC Immune Announces Upcoming Presentations at AD/PD™ 2024GlobeNewswire
ACIU
Earnings
- 11/3/23 - Miss
ACIU
Sec Filings
- 3/14/24 - Form F-3
- 3/14/24 - Form 6-K
- 3/14/24 - Form 20-F
- ACIU's page on the SEC website